Health Alert:

See the latest Coronavirus Information including testing sites, visitation restrictions, appointments and scheduling, and more.

Today, new data demonstrates that for patients at intermediate-risk for open-heart surgery, transcatheter aortic valve replacement (TAVR) with the latest generation of balloon-expandable device – SAPIEN 3 – is superior to surgery, resulting in better patient outcomes. This study, conducted by researchers in the Perelman School of Medicine at the University of Pennsylvania, in partnership with Edwards Lifesciences, the Cardiovascular Research Foundation, and 50 centers across the United States and Canada, was presented today at the American College of Cardiology 65th Annual Scientific Session in Chicago and simultaneously published online in The Lancet.

Share This Page: